Decoy Therapeutics Overview

  • Year Founded
  • 2020

Year Founded

  • Status
  • Private

  • Employees
  • 7

Employees

  • Latest Deal Type
  • Debt

  • Investors
  • 3

Decoy Therapeutics General Information

Description

Developer of antiviral medicines designed to rapidly address future pandemics. The company leverages AI technology to develop an anti-viral fusion inhibitor peptide nasal spray for SARS-Cov-2 prevention and early treatment as a complement to vaccines and build a pandemic preparedness platform, enabling healthcare professionals to offer an effective remedy against a broad spectrum of coronaviruses and enveloped viruses.

Contact Information

Website
decoytx.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Other Healthcare Technology Systems
Discovery Tools (Healthcare)
Biotechnology
Corporate Office
  • One Broadway
  • 14th Floor
  • Cambridge, MA 02142
  • United States
+1 (781) 000-0000

Decoy Therapeutics Timeline

2021202220232024
Date FoundedFinancing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Decoy Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Debt - General 01-Aug-2023 00000 Completed Pre-Clinical Trials
1. Seed Round 22-Apr-2021 00000 00000 Completed Pre-Clinical Trials
To view Decoy Therapeutics’s complete valuation and funding history, request access »

Decoy Therapeutics Patents

  • 5

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 000

    Granted

  • 5

    Pending

  • 000

    Expiring in next 12 mo

Decoy Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20240108735-A1 Methods and compositions for treating covid infections Pending 07-Feb-2022 0000000000
US-20220233683-A1 Methods and compositions for treating infections Pending 22-Jan-2021 0000000000
CA-3173121-A1 Methods and compositions for treating infections Pending 22-Jan-2021 0000000000
AU-2022209720-A1 Methods and compositions for treating infections Pending 22-Jan-2021 0000000000
EP-4281096-A1 Methods and compositions for treating infections Pending 22-Jan-2021 C07K14/165
To view Decoy Therapeutics’s complete patent history, request access »

Decoy Therapeutics Executive Team (7)

Name Title Board Seat Contact Info
Rick Pierce Co-Founder, Chief Executive Officer & Board Member
Michael Lipp Ph.D Chief Technology Officer
Barbara Hibner Ph.D Chief Scientific Officer, Senior Vice President, Research & Development & Board Member
Jodi Cooper Director, Operations
Peter Marschel Co-Founder, Chief Business Officer & Board Member
You’re viewing 5 of 7 executive team members. Get the full list »

Decoy Therapeutics Board Members (3)

Name Representing Role Since
Peter Marschel Decoy Therapeutics Co-Founder, Chief Business Officer & Board Member 000 0000
Rick Pierce Decoy Therapeutics Co-Founder, Chief Executive Officer & Board Member 000 0000
Shahin Gharakhanian MD Decoy Therapeutics Chief Medical Officer, Chairman & Scientific Advisory Board 000 0000
To view Decoy Therapeutics’s complete board members history, request access »

Decoy Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Decoy Therapeutics Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Massachusetts Life Sciences Center Government 000 0000 000000 0
Creative Destruction Lab Accelerator/Incubator 000 0000 000000 0
University of Toronto Entrepreneurship Accelerator/Incubator 000 0000 000000 0
To view Decoy Therapeutics’s complete investors history, request access »

Ready to get started?

Request a free trial

Decoy Therapeutics FAQs

  • When was Decoy Therapeutics founded?

    Decoy Therapeutics was founded in 2020.

  • Who is the founder of Decoy Therapeutics?

    Rick Pierce, Jodi Cooper, Peter Marschel, and Bradley Pentelute are the founders of Decoy Therapeutics.

  • Who is the CEO of Decoy Therapeutics?

    Rick Pierce is the CEO of Decoy Therapeutics.

  • Where is Decoy Therapeutics headquartered?

    Decoy Therapeutics is headquartered in Cambridge, MA.

  • What is the size of Decoy Therapeutics?

    Decoy Therapeutics has 7 total employees.

  • What industry is Decoy Therapeutics in?

    Decoy Therapeutics’s primary industry is Drug Discovery.

  • Is Decoy Therapeutics a private or public company?

    Decoy Therapeutics is a Private company.

  • What is Decoy Therapeutics’s current revenue?

    The current revenue for Decoy Therapeutics is 000000.

  • How much funding has Decoy Therapeutics raised over time?

    Decoy Therapeutics has raised $250K.

  • Who are Decoy Therapeutics’s investors?

    Massachusetts Life Sciences Center, Creative Destruction Lab, and University of Toronto Entrepreneurship have invested in Decoy Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »